Astellas Xospata (gilteritinib) Approved: Treatment Of Acute Myeloid Leukemia With FLT3 Mutation!
Feb,26,2021
Sanofi Terminates Multiple R&D Plans Such As Parkinson's Venglustat
Feb,25,2021
The US FDA Approves Tepmetko: The World's First Oral MET Inhibitor For The Treatment Of METex14 Skipping Changes In NSCLC
Feb,24,2021
Oral TYK2 Inhibitor Deucravacitinib Was Successfully Used In 2 Phase 3 Clinical Treatments Of Plaque Psoriasis!
Feb,23,2021
Biogen Waives Parkinson's Disease Drug Cinemanab
Feb,22,2021
Astellas Gilteritinib Obtains NMPA Conditional Approval
Feb,21,2021
Zeposia (ozanimod) For The Treatment Of Ulcerative Colitis Receives FDA Priority Review
Feb,20,2021
Antengene ATG-010 New Drug Marketing Application Was Accepted By The State Food And Drug Administration: Treatment Of Multiple Myeloma (MM)!
Feb,19,2021
The National Food And Drug Administration Of China Awarded Harbour BioMed FcRn Targeting Antibody Bartolizumab Breakthrough Drug Qualification!
Feb,18,2021
Pfizer Submits A Long-acting Human Growth Hormone Somatrogon Once A Week In Japan!
Feb,17,2021
CStone's Pralsetinib In The Treatment Of Chinese Patients With RET Fusion-positive Advanced Lung Cancer: Total Remission Rate Of 57%!
Feb,16,2021
Oxbryta (voxelotor) Enters The Review In The European Union And Is Listed In The US!
Feb,15,2021
Vertex's Triple Therapy Trikafta Has Been Given Priority Review By The US FDA, Expanding The Applicable Population (6-11 Years Old)!
Feb,14,2021
Inhibitor Odevixibat Has Been Given Priority Review By The US FDA!
Feb,13,2021
Zokinvy Is Listed In The US: Life Expectancy Is Extended By An Average Of 2.5 Years!
Feb,12,2021
Takeda's Next-generation ALK Inhibitor Alunbrig Is Approved By Japan
Feb,11,2021
Roche's Faricimab Is Successful In The Treatment Of Neovascular Age-related Macular Degeneration (nAMD) In Phase 3!
Feb,10,2021
AstraZeneca Calquence Has Higher Clinical Safety In Treating Leukemia (CLL) Phase 3!
Feb,09,2021
Opdivo+Cabometyx Program Was Approved By The US FDA
Feb,08,2021
The US FDA Approved The Inhibitor Lupkynis For The Treatment Of Adult Patients With Active Lupus Nephritis (LN).
Feb,07,2021